Inhaled rhGM-CSF (molgramostim) in the first randomised, double-blind, placebo-controlled, international trial in patients with autoimmune alveolar proteinosis (aPAP)

Francesco Bonella (Dusseldorf, Germany), Francesco Bonella, Yoshikazu Inoue, Inge Tarnow, Cecilia Ganslandt, Mette Vinge, Kim Arvid Nielsen, Cliff Morgan

Source: International Congress 2016 – Orphan diseases I
Session: Orphan diseases I
Session type: Thematic Poster
Number: 3877
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Francesco Bonella (Dusseldorf, Germany), Francesco Bonella, Yoshikazu Inoue, Inge Tarnow, Cecilia Ganslandt, Mette Vinge, Kim Arvid Nielsen, Cliff Morgan. Inhaled rhGM-CSF (molgramostim) in the first randomised, double-blind, placebo-controlled, international trial in patients with autoimmune alveolar proteinosis (aPAP). Eur Respir J 2016; 48: Suppl. 60, 3877

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial
Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs
Year: 2021



A Phase 2, double-blind, placebo-controlled study of N–acetylcysteine in combination with pirfenidone in patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 6
Year: 2014


Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial.
Source: Eur Respir J 2002; 20: 245
Year: 2002


Inhaled mannitol for non-cystic fibrosis bronchiectasis - results of a 12 month, multi-centre, double-blind, controlled study
Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Year: 2013


Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON)
Source: International Congress 2015 – Treatment of IPF
Year: 2015



LATE-BREAKING ABSTRACT: Inhaled mannitol for non-cystic fibrosis bronchiectasis: results of a 12 month, multi-centre, double-blind, controlled study.
Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment
Year: 2013



Efficacy of moxifloxacin for treatment of bronchial colonisation in COPD patients: a randomised, double-blind, placebo-controlled study
Source: Annual Congress 2007 - Treatment and care of COPD
Year: 2007



Heliox and alveolar oxygenation in patients with chronic obstructive pulmonary disease: a multicentre, randomised, crossover study
Source: Eur Respir J 2004; 24: Suppl. 48, 243s
Year: 2004

A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016

A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
Source: Eur Respir J, 53 (3) 1801992; 10.1183/13993003.01992-2018
Year: 2019



Bosentan does not improve outcome in patients with steroid-resistant pulmonary sarcoidosis – Results from a double-blind placebo-controlled phase 2 trial
Source: International Congress 2014 – Sarcoidosis
Year: 2014

A prospective randomised double-blind placebo controlled trial of venlafaxine in patients with stable chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2006; 28: Suppl. 50, 32s
Year: 2006

Pulmonary vasodilator therapy in severe COPD: a double-blind, placebo-controlled trial
Source: Eur Respir J 2007; 30: Suppl. 51, 525s
Year: 2007

LATE-BREAKING ABSTRACT: Prevention of COPD exacerbation by lysozyme: A double-blind, randomized, placebo-controlled study
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015

Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial
Source: Virtual Congress 2021 – ALERT: COPD
Year: 2021



A randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases
Year: 2007


RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
Source: Virtual Congress 2021 – ALERT: COPD
Year: 2021



The use of modafinil in patients with obstructive apnoea-hyponoea syndrome (OAHS). A randomized, placebo-controlled, double-blind study
Source: Eur Respir J 2001; 18: Suppl. 33, 419s
Year: 2001

Effects of a concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: A placebo-controlled double-blind trial
Source: Annual Congress 2010 - COPD exacerbation
Year: 2010

Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial.
Source: Virtual Congress 2020 – Chronic cough: only symptom or disease?
Year: 2020